SEA has received honoraria and/or travel expenses for lectures from Abbvie, Biogen, and Eisai, and has served on scientific advisory boards of Corte, has received consulting fees from Abbvie, Boyle Shaughnessy Law, Cognito Therapeutics, Eisai, EIP Pharma, M3 Biotech, Orthogonal Neuroscience, and Risen Pharmaceutical Technology Co, Ltd, and has received research grant support from NIH, Alzheimer's Association, Alzheimer's Drug Discovery Foundation, Challenger Foundation, John Sperling Foundation, Abbvie, Amylyx, Athira Pharma, Chromadex, EIP Pharma, Janssen Pharmaceuticals, Novartis, SEER Biosciences, and vTv Therapeutics, and has served on an MSDB and/or Advisory Board for Allyx Therapeutics, Bob's Last Marathon, Cassava, Cortexyme, Sage Therapeutics, and vTv Therapeutics. AA, PB, CC, GS, and MS are paid employees of Meso Scale Diagnostics, LLC. BTH has received funding from NIH, has served on an Advisory Board for Biogen, and he and/or his family has stock options in Novartis and Dewpoint.
DB has received funding from NIA, NINDS, and NIMH, has obtained compensation for serving on the Editorial Board of Belvoir Communications and is on the Advisory Board of the National Cell Repository for Alzheimer's Disease and the Risk Evaluation Education for Dementia (AGREED) study. TGI has received funding from NIH, MassCATS, and Cure Alzhimer's Fund, and served on the Eli Lilly DSMB. He has been advising for Merck, Wave LifeSciences, Arkuda, Axovant, and Alector.
BCD has received consulting fees from Acadia, Alector, Arkuda, Biogen, Denali, Eisai, Lilly, Merck, Novartis, Takeda, and Wave Lifesciences, royalties from Cambridge University Press, Elsevier, and Oxford University Press, and research grant support from NIH, Alzheimer's Association, and the Alzheimer's Drug Discovery Foundation. He has spoken at symposia sponsored by Janssen Alzheimer's Immunotherapy, and Pfizer. He is a site coinvestigator for Eli Lilly/Avid, Pfizer, Janssen Immunotherapy, and Navidea. KAJ has served as paid consultant for Bayer, GE Healthcare, Janssen Alzheimer's Immunotherapy, Siemens Medical Solutions, Genzyme, Novartis, Biogen, Roche, ISIS Pharma, AZTherapy, GEHC, Lundberg, and Abbvie. PK, CC, GS, MS, and SEA are named as co-inventors on a US patent application related to neurological biomarker assays that is jointly held by Massachusetts General Hospital and Meso Scale Diagnostics. Competing Interest StatementĪll authors have completed the ICMJE uniform disclosure form at and declare: The submitted work was supported by NIA, NIAID, NIH, NIH Division of AIDS, NIMH, NINDS, the Harvard NeuroDiscovery Center, and the Michael J Fox Foundation. Classification of Evidence This study provides Class II evidence that plasma levels of pTau181, tTau, NfL, and GFAP are associated with AD and that pTau181 and GFAP are associated with progression from MCI to AD dementia.
0 kommentar(er)
